Breast cancer is one of the most common cancers among women that is associated with
high mortality. Conventional treatments including surgery, radiotherapy, and chemotherapy …

Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been
considered promising therapeutic targets for cancer therapy. These cells have self-renewal …

Cancer stem cells drive tumor initiation, progression, and recurrence, which compromise the
effectiveness of anti-tumor drugs. Here, we report that demethylzeylasteral (DML), a …

Drug development is a lengthy and costly process that proceeds through several stages
from target identification to lead discovery and optimization, preclinical validation and …

TP53 is the most frequently mutated tumor suppressor gene in human cancer. The majority
of mutations of p53 are missense mutations, leading to the expression of the full length p53 …

Hypoxia induicible factor-1 alpha (HIF-1α) is a key transcription factor in cancer progression
and target therapy in cancer. HIF-1α acts differently depending on presence or absence of …

Many therapeutically active molecules are non-soluble in aqueous systems, chemically and
biologically fragile or present severe side effects. Lipid-based nanoparticle (LBNP) systems …

Therapeutic resistance and metastatic progression are responsible for the majority of cancer
mortalities. In particular, the development of resistance is a significant barrier to the efficacy …

Post-translational modification (PTM) of proteins is vital for increasing proteome diversity
and maintaining cellular homeostasis. If the writing, reading, and removal of modifications …

Breast cancer (BC) is the most prevalent cancer in women. BC is heterogeneous, with
distinct phenotypical and morphological characteristics. These are based on their gene …